Primary prevention of coronary heart disease: Integrating risk assessment with intervention

Circulation

Volumn 100, Issue 9, 1999, Pages 988-998

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Coronary disease; Prevention; Risk factors

Indexed keywords

ATHEROSCLEROTIC PLAQUE; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0033621070     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.9.988     Document Type: Review

References (90)

1. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould L, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke R, and Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
2. Constantinides P. Plaque hemorrhages, their genesis and their role in supraplaque thrombosis and atherogenesis. In: Glagov S, Newman WP, Schaffer SA, eds. Pathobiology of the Human Atherosclerotic Plaque. New York, NY: Springer-Verlag; 1990:393-411.
3. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
4. Ockene JK, Kuller LH, Svendsen KH, Meilahn E. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Public Health. 1990;80: 954-958.
5. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed. New York. NY: Raven Press, Ltd; 1995.
6. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
7. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk: the Medical Research Council's General Practice Research Framework. Lancet. 1998;351: 233-241.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TD, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
12. Downs JR, Clearfield M, Whitney E, Shapiro D, Beere PA, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
13. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995. J Am Coll Cardiol. 1996;27:957-1047.
14. National Cholesterol Education Program. Second report of the Expert Panel on Detection. Evaluation, and Treatment of high blood cholesterol (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
15. Wood D, De Backer G, Faergemann O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. J Hypertens. 1998;16:1407-1414.
16. Cleland JG. Can improved quality of care reduce the costs of managing angina pectoris? Eur Heart J. 1996;17:A29-A40.
17. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R, the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;340:1421-1425.
18. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
19. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
20. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83: 356-362.
21. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the American Heart Association's Task Force on Risk Reduction. Circulation. 1998;97:1876-1887.
22. Grundy SM, Wilhelmsen L, Rose R, Campbell RWF, Assman G. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J. 1990;11:462-471.
23. Eckel RH. Obesity in heart disease. A statement for healthcare professionals from the Nutrition Committee. American Heart Association. Circulation. 1997;96:3248-3250.
24. NHLBI Obesity Education Initiative Expert Panel. Clinical Guidelines on Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998.
25. Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B, Epstein S, Froelicher ESS, Froelicher VF, Pina IL, Pollock ML. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1996;94:857-862.
26. US Department of Health and Human Services. Physical activity and health: A report of the Surgeon General. Atlanta, Ga: Department of Health and Human Services. Centers for Disease Control and Prevention, National Center for Disease Prevention and Health Promotion; 1996.
27. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-969.
28. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991; 121:1283-1288.
29. DeFronzo KA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
30. Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. J Intern Med. 1998;243:265-274.
31. Bogardus C, Lillioja S, Mott D. Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians. J Clin Invest. 1984;73:800-805.
32. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
33. Sinacore DR, Gulve EA. The role of skeletal muscle in glucose transport, glucose homeostasis, and insulin resistance: implications for physical therapy. Phys Ther. 1993;73:878-891.
34. Rogers MA, King DS, Hagberg JM, Ehsani AA, Holloszy JO. Effect of 10 days of physical inactivity on glucose tolerance in master athletes. J Appl Physiol. 1990;68:1833-1837.
35. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, Passamani E, Rusell RO Jr, Alderman EL, Kouchoukas NT, Kaiser GC, Ryan TJ, Killip T, Fray D. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71:1854-1866.
36. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, Kaiser CG, Alderman E, Killip T III. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645-2657.
37. Storstein O, Engel I, Erikssen EJ, Thaulow E. Natural history of coronary artery disease studied by coronary arteriography a seven-year study of 795 patients. Acta Med Scand 1981;210:53-58.
38. Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect of patients' risk. Obes Res. 1998;6(suppl 1):8S-17S.
39. The Sixth Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure 1997. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. NIH publication 98-4080, 1997.
40. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
41. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994;308:363-366.
42. Karter AJ, Gazzaniga JM, Cohen RD, Casper ML, Davis BD, Kaplan GA. Ischemic heart disease and stroke mortality in African-American, Hispanic, and non-Hispanic white men and women, 1985-1991. West J Med. 1998; 169:139-145.
43. Williams R, Bhopal R, Hunt K. Coronary risk in a British Punjabi population: a comparative profile of non-biochemical factors. Int J Epidemiol. 1994;23: 28-37.
44. Pugh RN, Hossain MM, Malik M, el Mugamer IT, White MA. Arabian Peninsula men tend to insulin resistance and cardiovascular risk seen in South Asians. Trop Med Int Health. 1998;3:89-94.
45. Seedat YK, Mayet FG. Risk factors leading to coronary heart disease among the black, Indian and white peoples of Durban. J Hum Hypertens. 1996; 10(suppl 3):S93-S94.
46. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-367.
47. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2: 120-126.
48. Grundy SM. Age as a risk factor: you are as old as your arteries. Am J Cardiol. 1999;83:1455-1457.
49. Crouse JR III. Carotid and coronary atherosclerosis: what are the connections? Postgrad Med. 1991;90:175-179.
50. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR III. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb. 1991;11:1786-1794.
51. Crouse JR III, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation. 1995;92:1141-1147.
52. Visona A, Pesavento R, Lusiani L, Bonanome A, Cernerti C, Rossi M, Maiolino P, Pagnan A. Intimai medial thickening of common carotid artery as indicator of coronary artery disease. Angiology. 1996;47:61-66.
53. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CH, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
54. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and medial thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
55. Rumberger JA, Schwartz RS, Simons DB, Sheedy PF III, Edwards WD, Fitzpatrick LA. Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. Am J Cardiol. 1994;73:1169-1173.
56. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995;92:2157-2162.
57. Rumberger JA, Sheedy PF II, Breen JF, Fitzpatrick LA, Schwartz RS. Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification. Mayo Clin Proc. 1996;71:369-377.
58. Budoff MJ, Georgiou D, Brody A, Agatston AS, Kennedy J, Wolfkiel C, Stanford W, Shields P, Lewis RJ, Janowitz WR, Rich S, Brundage BH. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. Circulation. 1996;93:898-904.
59. Guerci AD, Spadaro LA, Popma JJ, Goodman KJ, Brundage BH, Budoff M, Lerner G, Vizza RF. Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults. Am J Cardiol. 1997;79:128-133.
60. Schmermund A, Baumgart D, Gorge G, Gronemeyer D, Seibel R, Bailey KR, Rumberger JA, Paar D, Erbel R. Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity. J Am Coll Cardiol. 1998;31:1267-1273.
61. Arad Y, Spadara LA, Goodman K, Lledo-Perez A, Sherman S,. Lerner G, Guerci AD. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation. 1996;93:1951-1953.
62. Guerci AD, Spadaro LA, Goodman KJ, Lledo-Perez A, Newstein D, Lerner G, Arad Y. Comparison of electron beam computed tomography scanning and conventional risk factor assessment for the prediction of angiographic coronary artery disease. JAm Coll Cardiol. 1998;32:673-679.
63. Bruce RA, Fisher LD, Hossack KF. Validation of exercise-enhanced risk assessment of coronary heart disease events: longitudinal changes in incidence in Seattle community practice. J Am Coll Cardiol. 1985;5: 875-881.
64. Multiple Risk Factor Intervention Trial Research Group. Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Cardiol. 1985;55:16-24.
65. Gordon DJ, Ekelund LG, Karon JM, Probstfield U, Rubenstein C, Sheffield LT, Weissfeld L. Predictive value of the exercise tolerance test for mortality in North American men: the Lipid Research Clinics Mortality Follow-up Study. Circulation. 1986;74:252-261.
66. Ekelund LG, Suchindran CM, McMahon RP, Heiss G, Leon AS, Romhilt DW, Rubenstein CL, Probstfield JL, Ruwitch JF. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol. 1989;14:556-563.
67. Rautaharju PM, Prineas RJ, Eifler WJ, Furberg CD, Neaton JD, Crow RS, Stamler J, Cutler JA. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. J Am Coll Cardiol. 1986;8:1-10.
68. Froelicher VF, Follansbee WP, Labovitz AJ, Myers J. Special application: screening apparently healthy individuals. In: Froelicher VF, Follansbee WP, Labovitz AJ, Myers J, eds. Exercise and the Heart. Boston, Mass: Mosby; 1993:208-229.
69. The Surgeon General's Report on the health benefits of smoking cessation: executive summary. MMWR Morb Mortal Wkly Rep. 1990;39:1-12.
70. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation. 1998;96:3243-3247.
71. Anderson KM, Castelli WP, Levy DL. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-2180.
72. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K-Y, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313-318.
73. American Diabetes Association. Standards of medical care for patients with diabetes mellirus (position statement). Diabetes Care. 1997;20:518-520.
74. Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med. 1998;158:2477-2483.
75. Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K, Rothman DL, Shulman GI. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subject. N Engl J Med. 1996;335:1357-1362.
76. Bailey CJ. Metformin: an update. Gen Pharmacol 1993;24:1299-1309.
77. Granberry MC, Schneider EF, Fonseca VA. The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy. 1998;18: 973-987.
78. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study to combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
79. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol. 1989;63:42H-47H.
80. Beresford SA, Boushey CJ. Homocysteine, folic acid, and cardiovascular disease risk. In: Benedict A, Deckelbaum RJ, eds. Preventive Nutrition: The Comprehensive Guide for Health Professionals. Totowa, NJ: Humana Press; 1997.
81. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99:178-182.
82. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234.
83. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, the MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol. 1989;14:49-57.
84. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 1984;54:718-721.
85. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LR, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith SC Jr, Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on risk reduction. Circulation. 1997;95:1683-1685.
86. Grundy SM. The role of cholesterol management in coronary disease risk reduction in elderly patients. Endocrinol Metab Clin North Am. 1998;27: 655-675.
87. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LR, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr. Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the task force on risk reduction. Circulation. 1997;95:2329-2331.
88. Centers for Disease Control and Prevention. Daily dietary fat and total food energy intakes: Third National Health and Nutrition Examination Survey: phase 1. MMWR Morbid Mortal Wkly Rep 1994;43:116-125.
89. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, Gorden DJ, Burt VL, Brown CD, Lippel K, Cleeman JL. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-3008.
90. Cater NB, Grundy SM. Lowering serum cholesterol with plant sterols and stanols: historical perspectives. In: Nguyen TT, ed. A Postgraduate Medicine Special Report: New Developments in Dietary Management of High Cholesterol. New York, NY: McGraw-Hill Co; 1998:6-14.